News

Good ideas are everywhere. That’s why at Zentynel we work without borders to support #biotech initiatives in different parts of the world. One of them is MultiplAI Health.

Did you know that cardiovascular diseases are the leading cause of mortality worldwide? And that diagnoses are often inaccurate and take time?

MultiplAI Health has come up with a creative, efficient and low-cost solution. It is a venture founded by a geneticist and a cardiologist (both Argentinean) and a Dutch patient, who developed a liquid biopsy for cardiovascular diseases, which allows analyzing health and disease risk based on genetic information from a blood sample.

Zentynel Frontier Investments has decided to invest US$700 thousand in a convertible note, with the purpose of vindicating and promoting this type of biopsy, which is very common in oncology, but this time in cardiovascular diseases.

MultiplAI Health has a very high impact potential, they target a very large market and are technically excellent. They have been invested in and incubated by lllumina, the world’s leading genetic analysis company.

We are very pleased to join their development; this is consistent with our aim to invest in biotech companies with global market potential.

Learn more about them on their website https://lnkd.in/dvYFdTAw and in this article from La Nación Argentina https://lnkd.in/dFNNZxUE